30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now

Matthew Fust

Track

Insider profile

Currently holds positions in Onyx Pharmaceuticals Inc, Sunesis Pharmaceuticals Inc, Ultragenyx Pharmaceutical Inc, Atara Biotherapeutics Inc and Crinetics Pharmaceuticals Inc

Performance

Overall performance
3.8
Performance over holding periods
3.8
30 days 90 days 120 days
Average return 2% 8.2% 15.1%
Success rate 100% 68% 82%
Transactions
6 0% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance

Positions

Position Company Period
Chief Financial Officer, Executive Vice President Onyx Pharmaceuticals Inc Jan. 5, 2009 -
Independent Director Sunesis Pharmaceuticals Inc May 1, 2005 -
Independent Director Ultragenyx Pharmaceutical Inc Feb. 6, 2014 -
Independent Director Atara Biotherapeutics Inc March 1, 2014 -
Independent Director Crinetics Pharmaceuticals Inc Feb. 1, 2018 -
Independent Director MacroGenics Inc March 6, 2014 - May 14, 2020
Independent Director Dermira Inc April 1, 2014 - Feb. 20, 2020
Matthew Fust's trades of Crinetics Pharmaceuticals Inc's stock


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2025-09-30 2025-09-26
PlS Planned sale
82,518 +41.2%
90.51
US$42,541 		82,518 +41.2% 90.51 US$42,541
2025-09-26 2025-09-26
PrS Proposed sale
72,835
226.15
US$2,293,713 		72,835 226.15 US$2,293,713
2024-10-18 2024-10-18
PrS Proposed sale
92,201
59.66
US$4,913,532 		92,201 59.66 US$4,913,532
2024-10-18 2024-10-18
PlS Planned sale
14,049 -41.1%
17.03
US$239,319 		14,049 -41.1% 17.03 US$239,319
2024-10-18 2024-10-17
PlS Planned sale
7,739 -27.8%
17.01
US$131,643 		7,739 -27.8% 17.01 US$131,643
2024-10-17 2024-10-17
PrS Proposed sale
7,739
17.01
US$131,643 		7,739 17.01 US$131,643
2024-03-22 2024-03-20
PlS Planned sale
17,500 -48.6%
45.50
US$796,250 		17,500 -48.6% 45.50 US$796,250
2024-03-22 2024-03-20
PlS Planned sale
17,500 -48.6%
43.58
US$762,650 		17,500 -48.6% 43.58 US$762,650
2024-03-22 2024-03-20
PlS Planned sale
12,500 -40.3%
43.57
US$544,625 		12,500 -40.3% 43.57 US$544,625
2024-03-22 2024-03-20
PlS Planned sale
12,500 -40.3%
43.57
US$544,625 		12,500 -40.3% 43.57 US$544,625
2024-03-20 2024-03-20
PrS Proposed sale
60,000
44.14
US$2,648,153 		60,000 44.14 US$2,648,153
2024-03-11 2024-03-07
S Sale
7,500 -33.5%
50.88
US$381,600 		7,500 -33.5% 50.88 US$381,600
2024-03-11 2024-03-07
S Sale
2,145 -8.8%
50.85
US$109,073 		2,145 -8.8% 50.85 US$109,073
2024-03-11 2024-03-07
S Sale
2,550 -9.4%
50.89
US$129,770 		2,550 -9.4% 50.89 US$129,770
2024-03-07 2024-03-07
PrS Proposed sale
12,195
50.88
US$620,439 		12,195 50.88 US$620,439
2022-07-15 2022-07-13
S Sale
5,700 -31.3%
20.96
US$119,455 		5,700 -31.3% 20.96 US$119,455
2021-11-05 2021-11-04
PlS Planned sale
13,354 -29.8%
19.50
US$260,403 		13,354 -29.8% 19.50 US$260,403
2021-11-03 2021-11-01
S Sale
8,954 -41.7%
25.50
US$228,327 		8,954 -41.7% 25.50 US$228,327
2021-07-13 2021-07-12
S Sale
5,000 -28.5%
20.71
US$103,550 		5,000 -28.5% 20.71 US$103,550
2020-07-08 2020-07-06
PlS Planned sale
6,181 -31.3%
90.00
US$556,290 		6,181 -31.3% 90.00 US$556,290
2020-07-06 2020-07-01
PlS Planned sale
5,000 -27.0%
85.00
US$425,000 		5,000 -27.0% 85.00 US$425,000
2020-05-19 2020-05-18
PlS Planned sale
1,875 -14.6%
75.00
US$140,625 		1,875 -14.6% 75.00 US$140,625
2020-04-24 2020-04-22
PlS Planned sale
1,875 -12.7%
65.00
US$121,875 		1,875 -12.7% 65.00 US$121,875
2019-09-16 2019-09-12
US Dermira Inc (DERM)
S Sale
6,000 -35.2%
8.77
US$52,636 		6,000 -35.2% 8.77 US$52,636
2019-02-08 2019-02-06
PlS Planned sale
6,924 -93.3%
29.38
US$203,427 		6,924 -93.3% 29.38 US$203,427